Fluidigm (NASDAQ:FLDM) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, August 1st. Analysts expect Fluidigm to post earnings of ($0.12) per share for the quarter.
Fluidigm (NASDAQ:FLDM) last announced its earnings results on Thursday, May 2nd. The medical research company reported ($0.44) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.30). Fluidigm had a negative return on equity of 43.75% and a negative net margin of 60.45%. The business had revenue of $30.10 million for the quarter, compared to the consensus estimate of $29.18 million. The firm’s revenue was up 19.4% compared to the same quarter last year. On average, analysts expect Fluidigm to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of FLDM opened at $12.06 on Wednesday. Fluidigm has a 12 month low of $5.50 and a 12 month high of $14.90. The stock’s 50 day simple moving average is $11.80. The company has a market capitalization of $822.03 million, a PE ratio of -15.08 and a beta of 2.16. The company has a debt-to-equity ratio of 0.30, a current ratio of 3.26 and a quick ratio of 2.86.
Several research analysts have recently commented on the stock. ValuEngine cut shares of Welbilt from a “hold” rating to a “sell” rating in a report on Wednesday, June 12th. BidaskClub cut shares of Westport Fuel Systems from a “buy” rating to a “hold” rating in a report on Friday, July 19th. Piper Jaffray Companies raised their target price on shares of Marvell Technology Group from $22.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, May 3rd. Finally, Zacks Investment Research raised shares of HB Fuller from a “sell” rating to a “hold” rating in a report on Wednesday, July 3rd. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $14.75.
In related news, Director Nicolas Barthelemy sold 5,100 shares of the stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $12.43, for a total transaction of $63,393.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Levin Easterly Partners Llc sold 186,759 shares of the stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $12.31, for a total transaction of $2,299,003.29. The disclosure for this sale can be found here. Insiders have sold a total of 1,152,660 shares of company stock worth $13,815,948 in the last quarter. 2.00% of the stock is currently owned by company insiders.
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.
Further Reading: Golden Cross
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.